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Since majority of systemically administered mesenchymal stem cells (MSCs) become entrapped within the lungs, we used
metastatic model of lung cancer, induced by intravenous injection of Lewis lung cancer 1 (LLC1) cells, to investigate the
molecular mechanisms involved in MSC-mediated modulation of metastasis. MSCs signiﬁcantly augmented lung cancer
metastasis, attenuate concentrations of proinﬂammatory cytokines (TNF-α, IL-17), and increase levels of immunosuppressive
IL-10, nitric oxide, and kynurenine in sera of LLC1-treated mice. MSCs profoundly reduced inﬁltration of macrophages,
TNF-α-producing dendritic cells (DCs), TNF-α-, and IL-17-producing CD4+ T cells but increased IL-10-producing CD4+ T
lymphocytes in the lungs of tumor-bearing animals. The total number of lung-inﬁltrated, cytotoxic FasL, perforin-expressing,
TNF-α-, and IL-17-producing CD8+ T lymphocytes, and NKG2D-expressing natural killer (NK) cells was signiﬁcantly reduced
in LLC1+MSC-treated mice. Cytotoxicity of NK cells was suppressed by MSC-conditioned medium. This phenomenon was
abrogated by the inhibitors of inducible nitric oxide synthase (iNOS) and indoleamine 2,3-dioxygenase (IDO), suggesting the
importance of iNOS and IDO for MSC-mediated suppression of antitumor cytotoxicity of NK cells. This study provides the
evidence that MSCs promote lung cancer metastasis by suppressing antitumor immune response raising concerns regarding
safety of MSC-based therapy in patients who have genetic susceptibility for malignant diseases.
1. Introduction
Mesenchymal stem cells (MSCs) are self-renewable adult
stem cells with ﬁbroblast-like morphology that can be found
in almost all postnatal tissues [1]. MSCs are currently used in
broad number of clinical trials due to their multilineage
diﬀerentiation potential and immunomodulatory character-
istics. MSCs diﬀerentiate into the cells of mesodermal origin
in vitro and in vivo, but recently published data suggest
that under speciﬁc culture conditions, plasticity of MSCs
should be extended to nonmesenchymal lineages of neu-
roectodermal (neurons, astrocytes, and oligodendrocytes)
or endodermal (hepatocytes) origin [2].
MSCs may promote angiogenesis by transdiﬀerentiation
into endothelial cells and through the production of several
proangiogenic factors (hepatocyte growth factor (HGF),
vascular endothelial growth factor (VEGF), transforming
growth factor beta (TGF-β), and interleukin- (IL-) 6) [3].
MSCs suppress immune response by attenuating migra-
tion and maturation of dendritic cells (DCs), promoting
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alternative activation of macrophages, and reducing prolifer-
ation, activation, and eﬀector function of B and T lympho-
cytes, natural killer (NK), and natural killer T (NKT) cells [1].
Although proangiogenic and immunosuppressive char-
acteristics of MSCs are beneﬁcial in the treatment of degener-
ative and autoimmune diseases, they can represent a serious
problem if patient that received MSCs have primary or
metastatic tumor. Accordingly, safeness of MSC-based ther-
apy is still a matter of debate. The primary concern was the
potential malignant transformation of the administered
MSCs. A recent meta-analysis partly reassured the scientiﬁc
community by showing that malignancies which were
noticed in MSC-treated patients occurred only in patients
with previous or current malignancies, with no formation
of de novo tumors [4]. However, potential of MSCs to pro-
mote neovascularization and suppress antitumor immunity
is still existing as major concerns regarding the safety of
MSC-based therapy and should be further explored in pre-
clinical and clinical studies.
MSCs have at least three functions that can promote
tumor metastasis: homing to the site where tissues are
damaged, including metastatic lesions, production of immu-
nomodulatory factors, and secretion of proangiogenic cyto-
kines and growth factors that promote neovascularization
enabling metastasis of tumor cells [1, 4].
Lung-inﬁltrated cells as well as their products which
contribute to tumor escape mechanisms and host immuno-
suppression are emerging as important mediators in promot-
ing lung cancer growth and metastasis [5, 6].
Since vast majority of intravenously injected MSCs ini-
tially become entrapped within the lungs where MSCs inter-
act with tumor-inﬁltrated immune cells [1], we used
metastatic model of murine lung cancer to investigate molec-
ular and cellular mechanisms involved in MSC-mediated
modulation of antitumor immune response and progression
of lung cancer metastasis.
Herewith, we showed that intravenous application of
MSCs in tumor-bearing mice signiﬁcantly suppressed sys-
temic antitumor immune response, reduced total number
of lung-inﬁltrated DCs, macrophages, CD4+ T lymphocytes,
CTLs, and NK cells, and attenuated antitumor cytotoxicity of
CTLs and NK cells resulting with the expansion of metastatic
lesions in the lungs.
2. Materials and Methods
2.1. Cells.MSCs isolated from bone marrow of C57BL/6 mice
were purchased from Gibco (Catalog number S1502-100).
The cells were cultured in complete Dulbecco’s Modiﬁed
Eagle Medium (DMEM) containing 10% heat-inactivated
fetal bovine serum (FBS), 100 IU/mL penicillin G, and
100μg/mL streptomycin (Sigma-Aldrich, Munich, Germany),
at 37°C in a 5% CO2 incubator. MSCs in passage 3 were
used throughout the experiments.
The cell line of murine lung carcinoma (Lewis lung
cancer 1, LLC1) (3LL, H2b), derived from the lungs of
C57BL mice implanted with Lew (Lewis) lung cancer, was
purchased from the American Type Culture Collection
(ATCC) (Catalog number CRL-1642™). Cells were routinely
grown in suspension in complete DMEMmedium, at 37°C in
a 5% CO2 incubator. LLC1 cells in passage 3 were used
throughout the experiments.
2.2. Generation of MSC-Conditioned Medium (MSC-CM).
MSCs were seeded at a density of 10,000 cells/cm2. In order
to collect the MSC-CM, MSCs were ﬁrst cultured in serum-
containing complete medium and incubated at 37°C in a
humid atmosphere with 5% CO2. At 80% conﬂuence, the
cells were washed twice with 1X phosphate-buﬀered saline
(PBS, Invitrogen), and the medium was then changed to
serum-free medium. After 48 h, the medium was collected,
centrifuged at 13000×g at 4°C for 10min, and stored at
−80°C until used [7].
2.3. Pharmacological Inhibition of Indoleamine 2,3-
Dioxygenase (IDO) and Inducible Nitric Oxide Synthase
(iNOS).MSCs were cultured for 48 h in culture medium con-
taining 1mM 1-methyltryptophan, (1-MT, Sigma-Aldrich,
St. Louis, MO), an inhibitor of IDO enzymatic activity [8].
To block iNOS activity, MSCs were cultured for 48h in
the presence of 1mM of an iNOS inhibitor, L-NG-mono-
methyl arginine citrate (L-NMMA, Sigma-Aldrich, St. Louis,
MO) [9].
2.4. Animals. 6–8-week-old C57Bl/6 male mice were used. All
animals received human care, and all experiments were
approved by and conducted in accordance with the Guide-
lines of the Animal Ethics Committee of the Faculty of
Medical Sciences of the University of Kragujevac, Serbia.
Mice were housed in a temperature-controlled environment
with a 12-hour light-dark cycle and were administered with
standard laboratory chow and water ad libitum.
2.5. Induction of Experimental Metastasis and Systemic
Application of MSCs. Experimental metastases were induced
by intravenous injection of 5× 104 LLC1 cells [10]. Mice
intravenously received either 5× 105 MSCs or saline one
week after injection of LLC1 cells. Mice were sacriﬁced on
the 28th day of the experiment, as previously described [5].
2.6. Histopathological Analysis. All mice were sacriﬁced in an
atmosphere saturated with diethyl ether (BETA HEM, Bel-
grade), and the lungs were isolated for histopathological
analysis of metastatic colonies 28 days after tumor induction.
The isolated lungs were ﬁxed in 10% formalin and
embedded in paraﬃn, and consecutive 4μm tissue sections
mounted on slides. Sections were stained with hematoxylin
and eosin (H&E) and examined under low-power (100x)
light microscopy-equipped digital camera (Zeiss Axioskop
40, Jena, Germany). Metastases were veriﬁed by light micros-
copy (magniﬁcation 10x and 40x) as characteristic brown-
black pigmented “hot spots” with giant multinucleated cells
clearly limited by the surrounding lung tissue.
2.7. Immunohistochemistry. For immunohistochemical stain-
ing, paraﬃn-embedded sections (4μm) of mouse lung tissue
were used. Heat-mediated antigen retrieval in citrate buﬀer
(pH=6.0) was performed. Deparaﬃnized tissue-sections
were incubated with primary mouse anti-CD3 (sc-20047,
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Santa Cruz Biotechnology), anti-CD4 (ab183685, Abcam),
anti-CD68 (ab49777, Abcam), anti-TNF-α antibody (ab6671,
Abcam), and anti-IL-17 (ab79056, Abcam). Staining was
visualized by using Mouse Speciﬁc HRP/DAB Detection IHC
Kit (ab64259, Abcam) for CD3 and CD68, and rabbit speciﬁc
HRP/AEC detection IHC Kit (ab94361, Abcam) for CD4,
TNF-α, and IL-17. Sections were counterstained withMayer’s
hematoxylin. Sections were photomicrographed with a digital
cameramountedon lightmicroscope (OlympusBX51, Japan),
digitized, and analyzed.
2.8. Isolation of Lung-Inﬁltrated Immune Cells. The lungs,
obtained from control, LLC1 and LLC1+MSC-treated mice
at the 28th day of the experiment, were washed with sterile
phosphate-buﬀered saline (PBS) and placed in Petri dishes
with DMEM supplemented with 10% FBS. The dissected
lung tissue was incubated in medium that contained Collage-
nase Type IV (0.5mg/mL) and type IV bovine pancreatic
DNAse (Roche Diagnostic; 1mg/mL) at 37°C for 45min.
The cells were ﬁltered through a 100μm nylon cell strainer
into a clean 50mL conical tube. Then, cells were pelleted by
centrifuging 10min at 300×g, at 10°C. Red blood cells were
depleted with a lysis buﬀer (0.144M NH4Cl, 0.0169M TRIS
base, pH7.4) at 37°C in a 5% CO2 atmosphere for 5min [11].
2.9. Flow Cytometry Analysis and Intracellular Staining of
Lung-Inﬁltrated Immune Cells. Lung-inﬁltrated immune
cells were screened for various cell surface and intracellular
markers with ﬂow cytometry. Brieﬂy, 1× 106 cells were incu-
bated with anti-mouse CD45, F4/80, CD4, CD8, CD11c,
CD11b, CD49b, FasL, CD107, perforin, NKG2Dmonoclonal
antibodies conjugated with ﬂuorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin chlorophyll protein
(PerCP), or allophycocyanin (APC) (all from BD Biosci-
ences, San Jose, CA, USA) following the manufacturer’s
instructions. Immune cells derived from the lungs were con-
comitantly stained for the intracellular content of TNF-α, IL-
10, and IL-17 by using the ﬁxation/permeabilization kit and
anti-mouse monoclonal antibodies conjugated with ﬂuores-
cein isothiocyanate (FITC), phycoerythrin (PE), peridinin
chlorophyll protein (PerCP), and allophycocyanin (APC)
(BD Biosciences). For intracellular cytokine staining, cells
were stimulated with 50 ng/mL PMA and 500ng/mL iono-
mycin for 5 h, and GolgiStop (BD Biosciences) was added.
Cells were ﬁxed in Cytoﬁx/Cytoperm, permeated with 0.1%
saponin, and stained with ﬂuorescent Abs. Flow cytometric
analysis was conducted on a BD Biosciences’ FACSCalibur
and analyzed by using the ﬂowing software analysis program.
2.10. Measurement of Cytokines and Growth Factors in Sera
of Tumor-Bearing Mice. Levels of TNF-α, IL-17, IL-10, and
HGF in the mouse serum at the 14th, 21st, and 28th days
of the experiment were measured using ELISA kits speciﬁc
for the mouse cytokines (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
Serum concentrations of nitric oxide (NO)weremeasured
by Griess reagent while IDO activity was determined by spec-
trophotometric measuring of kynurenine since IDO catalyzes
the metabolism of tryptophan in the kynurenine [12].
Concentrations of NO and kynurenine were determined in
mouse sera at the 14th, 21st, and 28th days of the experiment.
2.11. Isolation of NK Cells by Magnetic Cell Sorting. At the
28th day of the experiment, NK cells were isolated from the
spleens of LLC1 and LLC1+MSC-treated mice by magnetic
cell sorting according to the manufacturer’s instructions.
Single-cell suspensions of mononuclear cells derived from
the spleens were labeled with monoclonal anti-mouse anti-
bodies against CD49b, and microbeads conjugated to mono-
clonal anti-biotin antibody (Miltenyi Biotec). The labeled
cells were subsequently depleted by separation over a MACS
Column (Miltenyi Biotec), which was placed in the magnetic
ﬁeld of a MACS Separator (Miltenyi Biotec). Isolated NK
cells were then used in the coculture experiments and cyto-
toxicity assay as puriﬁed NK cells.
2.12. Cytotoxicity Assay. The DP version of the xCELLigence
system (Roche) was used in this study for the determination
of NK cell cytotoxicity. The DP version comprises a measure-
ment unit housed within a standard tissue culture incubator
with 3 stations that each takes E16 plates (each E16 plate
has 16 wells). 100μL of complete medium was added to each
well, and background impedance on the plates was measured
on the xCELLigence RTCA DP instrument at 37°C and 5%
CO2. LLC1 cells were used as targets for NK cells. Seeding
density of 4× 104 LLC1 cells/well was considered optimal
and used for all assays. Eﬀector to target ratio (E : T ratio)
10 : 1 was used [13]. LLC1 cells were resuspended in DMEM
with 10% FCS at 4× 105 cells per milliliter. A total of 100μL
tumor cells were added to each well of the E16 plate,
which was then placed in the xCELLigence RTCA DP.
NK cells, isolated from LLC1 and LLC1+MSC-treated
mice at the 28th day of the experiment, were counted
and resuspended at a concentration of 4× 106 cells per
milliliter in DMEM+10% FCS media. Then, 100μL NK
cells or media alone were added to the respective wells.
The E-plate 16 was placed in the xCELLigence RTCA
DP, and impedance measurements were recorded every
15min for 24 hours at 37°C and 5% CO2. NK cell-
mediated death of tumor cells was monitored in real time
and was indicated by a decrease in cell index. Data were
analyzed with RTCA Software 1.2 (ACEA Biosciences).
2.13. Statistical Analysis. The results were analyzed using the
Student t-test. All data in this study were expressed as the
mean± standard error of the mean (SEM). Values of
p < 0 05 were considered as statistically signiﬁcant.
3. Results
3.1. Intravenous Injection of MSCs Signiﬁcantly Augmented
Lung Cancer Metastasis. First, we investigated whether
systemic application of MSCs could modulate spontaneous
LLC1 tumor cell metastasis to the lungs. We observed
that LLC1+MSC-treated tumor-bearing mice exhibited
increased numbers of lung metastasis (Figure 1(a)) com-
pared to animals that received only LLC1 cells. Signiﬁ-
cantly higher number of tumor cells with pleomorphic
nuclei, arranged in aggregated forms, was noticed in
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the lungs of MSC-treated tumor-bearing animals at the 28th
day of the experiment. Although perivascular inﬁltration of
tumor cells was also noticed in the lungs isolated from
LLC1-treated mice, expansion of malignant tissue in these
mice was notably lower in comparison to LLC1+MSCs-
treated animals in which lung tissues were almost completely
displaced with tumor cells (Figure 1(a)). Histological score of
lung tissue conﬁrmed extensive malignancy in LLC1-treated
mice that intravenously received MSCs (Figure 1(b)).
3.2. MSCs Altered Serum Levels of Cytokine and Growth
Factors That Played Important Role in Antitumor Immune
Response. In order to explore whether MSC-dependent
expansion of metastatic lesions in the lungs is a consequence
of their eﬀects on systemic immune response, cytokine con-
centration was determined in sera of tumor-bearing animals
at the 14th, 21st, and 28th days of the experiment. In
accordance with the histological analysis, MSCs signiﬁcantly
alter serum levels of cytokines and growth factors that play
important role in antitumor immune response at all mea-
sured time points. The concentrations of antitumor cytokines
TNF-α (Figure 1(c)) and IL-17 (Figure 1(d)) were signiﬁ-
cantly lower while the concentrations of immunosuppressive
IL-10 (Figure 1(e)), kynurenine (Figure 1(g)), and NO
(Figure 1(h)) were signiﬁcantly higher in sera of LLC1-
treated mice that received MSCs. There was not any signiﬁ-
cant diﬀerence in serum levels of immunomodulatory HGF
between experimental groups (Figure 1(f)).
3.3. MSCs Signiﬁcantly Reduced Total Number of DCs,
Macrophages, and CD4+ Helper T Cells in the Lungs of
LLC1-Treated Mice and Altered Their Cytokine Proﬁle.
Next, we analyzed cellular make-up of the lungs 28 days
after tumor injection in order to determine cellular targets
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Figure 1: MSCs promote lung cancer metastasis. (a) Representative H&E stained mouse lungs obtained at the 28th day of the experiment.
H&E staining images of liver tissue samples are shown at the same magniﬁcations (×100). (b) Histological score of lung tissue determined
at the 28th day of the experiment. (c) Serum concentrations of TNF-α, (d) IL-17, (e) IL-10, and (f) HGF measured at the 14th, 21st, and
28th days of the experiment. (g) The level of kynurenine and (h) NO in mouse sera at the 14th, 21st, and 28th days of the experiment.
Data presented as mean± SEM; n = 10 mice per experimental groups. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001.
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of MSC-mediated suppression of antitumor immune
response in LLC1-treated animals. MSCs profoundly reduced
inﬁltration of CD45+ leukocytes into the lung parenchyma
(p < 0 01; Figure 2(a)). Flow cytometry analysis showed
that a total number of CD45+F4/80+ macrophages
(Figure 2(b), p < 0 01), CD45+CD11c+CD11b+ inﬂamma-
tory DCs (Figure 2(c), left panel, p < 0 05), and CD4+ helper
T cells (Figure 2(d), p < 0 01) were signiﬁcantly lower in the
lungs of tumor-bearing mice that received MSCs.
Intracellular staining revealed that systemic application
of MSCs reduces inﬁltration of TNF-α-producing DCs
(Figure 2(c), right panel, p < 0 05), TNF-α-producing
(Figure 2(d), middle panel, p < 0 01), and IL-17-producing
CD4+ helper T cells (Figure 2(d), right panel, p < 0 05) and
increases the presence of CD4+ T cells that produce immu-
nosuppressive IL-10 (Figure 2(e), p < 0 05).
Immunohistochemical analysis conﬁrmed these ﬁnd-
ings. Intravenous injection of MSCs reduced the presence
of CD3+ T lymphocytes (Figure 3(a)), CD4+ T helper
cells (Figure 3(b)), CD68+ macrophages (Figure 3(c)),
TNF-α-producing (Figure 3(d)), and IL-17-producing cells
(Figure 3(e)) in the lungs of LLC1-treated mice 28 days
after tumor induction.
3.4. MSCs Reduced Inﬁltration of CTLs in the Lungs of LLC1-
Treated Mice and Attenuated Expression of FasL, Perforin,
and CD107 on Their Surface. Intravenous injection of MSCs
signiﬁcantly reduce total number of cytotoxic CD8+CTLs
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Figure 2: MSC treatment reduces inﬂux of DCs, macrophages, and CD4+ T cells, in the metastatic model of lung cancer, and altered their
cytokine proﬁle. Total numbers of (a) CD45+, (b) CD45+ F4/80+, (c) CD45+CD11c+CD11b+, and CD11c+TNF-α+ cells in the lungs of
control, LLC1, and LLC1+MSC-treated mice at the 28th day of the experiment. (d) Total number and representative ﬂow cytometry dot
plots of CD4+, TNF-α-, and IL-17-producing CD4+ cells at the 28th day of the experiment. (e) Total numbers of lung-inﬁltrating
CD4+ IL-10+ cells at the 28th day of the experiment. Values are mean± SEM (n = 10 per group). ∗p < 0 05, ∗∗p < 0 01.
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obtained at the 28th day of the experiment (×20, ×40). (a) CD3+ cells, (b) CD4+ cells, and (c) CD68+ macrophages were present in
higher numbers in lungs of LLC1-treated mice compared to LLC1+MSCs and control groups. Expression of (d) TNF-α and (e) IL-17 in
lung tissue was higher in lungs of LLC1-treated mice compared to LLC1+MSC and control groups.
6 Stem Cells International
30
25
20
15
10
5
0
⁎⁎
CD8+
3
25
2
1.5
1
0.5
0
⁎
CD8+ FasL+
14
12
10
8
4
6
2
0
CD8+ perforin+
⁎
2.5
2
1.5
1
0.5
0
⁎⁎
CD8+ CD107+
25
20
15
10
5
0
⁎⁎
CD8+ TNF-훼+
16
24
12
10
8
6
4
2
0
⁎⁎
CD8+ IL-17+
10
24
SS
C-
H
22.24%
17% 11%
3%15.3%
9%26.1%
CD8 FITC 1000
10
24
SS
C-
H
7.11%
CD8 FITC 1000
10
24
SS
C-
H
10
24
SS
C-
H
10
24
SS
C-
H
10
24
SS
C-
H
10
24
SS
C-
H
Perforin APC Perforin APC
CD107 PECD107 PE
10
24
SS
C-
H
FasL PE 10001000
1000 1000
10001000
FasL PE
LLC1 + MSCS
Control
LLC1
LLC1 + MSCs
(a)
(b)
(c)
(d)
(e) (f)
LLC1
Ce
lls
Ce
lls
Ce
lls
Ce
lls
Ce
lls
Ce
lls
×105
×105
×105
×105
×105 ×105
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(Figure 4(a), p < 0 01) in the lungs of LLC1-treated mice at
the 28th day of the experiment. Moreover, analysis of
cytotoxic molecules involved in CTL-mediated antitumor
immune response (FasL, perforin, and CD107) showed that
MSCs managed to attenuate inﬂux of FasL+CTLs
(Figure 4(b), p < 0 05), perforin +CTLs (Figure 4(c),
p < 0 05), and CD107+CTLs (Figure 4(d), p < 0 01) in the
lungs of tumor-bearing animals.
Intracellular staining revealed that systemic application
of MSCs attenuate the capacity of CTLs to produce antitu-
mor cytokines (Figures 4(e)-4(f)). There were signiﬁcantly
lower number of TNF-α-producing (Figure 4(e), p < 0 01)
and IL-17-producing CTLs (Figure 4(f), p < 0 01) in
MSC+LLC1-treated mice when compared to LLC1-only
treated animals.
3.5. Antitumor Cytotoxicity of NK Cells Was Signiﬁcantly
Attenuated in MSC+LLC1-Treated Mice in Paracrine, NO,
and IDO-Dependent Manner. As determined by ﬂow cytom-
etry, 28 days after tumor induction, the presence of CD49b
+NK cells was signiﬁcantly reduced in LLC1+MSC-treated
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Figure 5: MSCs attenuate antitumor cytotoxicity of NK cells in iNOS and IDO-dependent manner. The total number of (a) CD49b+ and (b)
CD49b+NKG2D+ cells in the lungs of control, LLC1, and LLC1+MSC-treated mice at the 28th day of the experiment. (c-d). The results
obtained by xCELLigence system showed cytotoxic activity of NK cells against LLC1 target cells. Data presented as mean± SEM; n = 10
mice per experimental groups. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001.
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mice when compared to the LLC1-only treated animals
(Figure 5(a), p < 0 01).
Moreover, the total number of NK cells that express acti-
vation receptor NKG2D, involved in antitumor immune
response, was notably lower in the lungs of tumor-bearing
mice that receivedMSCs (Figure 5(b), p < 0 05). Accordingly,
the results obtained by xCELLigence system for monitoring
real-time cytotoxicity showed that NK cells isolated from
LLC1+MSC-treated mice were signiﬁcantly less cytotoxic
against LLC1 cells then NK cells isolated from animals that
received only LLC1 cells (Figure 5(c)), indicating that intra-
venous injection of MSCs signiﬁcantly reduced antitumor
cytotoxicity of NK cells.
To directly demonstrate that soluble factors and not cell
to cell contact were responsible for the MSC-mediated inhi-
bition of NK cell cytotoxicity against LLC1 cells, eﬀects of
MSC-CM were evaluated. As it is shown in Figure 5(d),
MSC-CM signiﬁcantly suppressed cytotoxicity of NK cells
against LLC1 cells. This phenomenon was completely abro-
gated in the presence of iNOS inhibitor (L-NMMA) or IDO
inhibitor (1-MT), suggesting iNOS and IDO as important
factors for MSC-mediated suppression of antitumor cytotox-
icity of NK cells (Figure 5(d)).
4. Discussion
It is well known that MSCs are inherently tumor-homing
cells that, few hours after systemic injection, migrate in the
lungs [14, 15]. Many receptors, extracellular matrix proteins,
and soluble tumor-derived factors have been reported to
eﬀect tumor tropism of intravenously injected MSCs [15,
16]. Most recently, it was shown that macrophage migration
inhibitory factor (MIF)/CXCR4 and monocyte chemoattrac-
tant protein-1 (MCP-1)/CCR2 pathways are responsible for
migration of MSCs in the tumor microenvironment of the
lungs [15, 16]. MIF secreted from tumor cells attracts MSCs
to the lungs in CXCR4-dependent manner. Knockdown of
either CXCR4 or MIF abrogates MSC homing to tumors in
an in vivo pulmonary metastasis model [15]. Similarly, hom-
ing ability ofMSCswas suppressed after either knocking down
the expression of MCP-1 in lung cancer cells or blocking
CCR2 expressed on the surface ofMSCs, indicating the impor-
tant role of MCP-1/CCR2 axis in the tropism ofMSCs to lung
tumors [16]. Immediately after their engraftment, MSCs
interact with tumor-inﬁltrated immune cells, aﬀecting antitu-
mor immune response [17]. Accordingly, ﬁndings related to
the MSC-based modulation of antitumor immunity could
have important implications for clinical applications ofMSCs.
Here, we provide the evidence that systemic application
of MSCs in tumorbearing animals promotes expansion of
lung metastasis by suppressing antitumor immune response
through the inhibition of innate (DCs, NK cells) and adaptive
(CD4+ T helper, CD8+CTLs) immunity.
Signiﬁcantly lower number of macrophages (Figures 2(b)
and 3(c)), DCs (Figure 2(c)), eﬀector CD4+ helper T cells
(Figures 2(d) and 3(b)), and CD8+CTLs (Figures 4(a), 4(b),
4(c), 4(d), 4(e), and 4(f)) as well as reduced number and cyto-
toxicity of NK cells (Figure 5) indicates that systemic
application of MSCs aﬀected both inductive and eﬀector
phase of antitumor immune response.
Intravenous injection of MSCs suppresses, almost instan-
taneously, the migration of DCs to the draining lymph nodes
signiﬁcantly aﬀecting the ability of DCs for antigen presenta-
tion to CD4+ T cells and cross-presentation to CD8+ T cells
[18, 19]. Accordingly, signiﬁcantly reduced number of
CD11c+CD11b+DCs (Figure 2(c)) was accompanied with
reduced number of CD4+ (Figures 2(d) and 3(b)) and
CD8+ T cells (Figure 3(a)) in the lungs of LLC1-treated
mice that received MSCs.
Maturation of DC is also impaired by MSCs [20, 21]. DC
exposed to TNF-alpha and MSCs failed to upregulate matu-
ration markers [19]. On turn, immature DCs are strongly
hampered in their ability to produce TNF-α and other proin-
ﬂammatory cytokines that inhibit tumor growth and metas-
tasis [22]. In line with these observations, downregulated
serum levels of TNF-α (Figure 1(c)) were accompanied with
lower number of TNF-α-producing DCs in the lungs of
LLC1+MSCs-treated mice when compared to LLC1-only
treated animals (Figure 2(c)).
In addition to suppression of naïve T cell activation,
MSCs are able to induce suppression of eﬀector CD4+ T
helper cells that is mainly mediated through the production
of soluble factors including IDO, NO, IL-10, prostaglandin
E2 (PGE2), HGF, and TGF-β [23]. Accordingly, intrave-
nous injection of MSCs resulted with higher serum levels
of IL-10 (Figure 1(e)), kynurenine (Figure 1(g)), and NO
(Figure 1(h)) that was followed by reduce number of lung-
inﬁltrated eﬀector CD4+ T cells (Figures 2(d) and 3(b)) that
produce antitumor cytokines TNF-α and IL-17 (Figure 2(d)).
Progressive inﬂammatory diseases, including tumors, are
associated with the loss of IL-17-producing CD4+ Th17 cells
and a reciprocal increase in the fraction of the immunosup-
pressive IL-10-producing CD4+ T lymphocytes both in
peripheral blood and in inﬂamed tissues [24]. MSC-derived
IDO is an enzyme that has powerful immunomodulatory
eﬀects, resulting from its enzymatic activity, which leads
to catabolism of the essential aminoacid L-tryptophan to
L-kynurenine [25]. Metabolites of the L-kynurenine pathway
have been shown to act as critical molecular switch that stim-
ulates immunosuppressive properties of IL-10producing T
cells and simultaneously blocks their reprogramming into
IL-17-producing eﬀector T cells [26]. Accordingly, herewith,
we showed that injection of MSCs increased serum levels of
kynurenine in LLC1-treated mice (Figure 1(g)), accompanied
with increased number of IL-10-producing CD4+ T lympho-
cytes and decreased number of IL-17-producing Th17 cells
(Figure 2(d)).
As described above, MSCs attenuate the capacity of DC
for cross-presentation and activation of CD8+ T cells [18].
Additionally, MSCs suppress the proliferation of CTLs and
inhibit surface expression of molecules which are involved
in CTL-mediated cytotoxicity against tumor cells [27]. In line
with these ﬁndings, signiﬁcantly lower number of lung-
inﬁltrated CD8+CTLs expressing FasL (Figure 4(b)) and
perforin (Figure 4(c)) was noticed in MSC+LLC1-treated
mice when compared to LLC1-only treated animals indi-
cating that systemic administration of MSCs suppressed
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both perforin- and FasL-mediated mechanisms of antitumor
cytotoxicity of CTLs.
MSCs suppress proliferation and cytotoxicity of NK
cells, as well [28–30]. This inhibitory eﬀect of MSCs is
associated with the downregulated expression of the activat-
ing NK cell receptors, such as NKG2D, and is primarily
mediated by IDO, PGE2, and TGF-β1 [29, 30]. Herewith,
we showed that MSCs reduce total number of lung-
inﬁltrated NKG2D-expressing NK cells in LLC1-treated
mice (Figure 5(b)) and signiﬁcantly attenuate their cytotox-
icity against lung cancer cells in vitro (Figure 5(c)). Both
iNOS and IDO inhibitors managed to almost completely
restore cytotoxic activity of NK cells against LLC1 cells
in vitro (Figure 5(d)), suggesting the importance of both
iNOS and IDO signaling for MSC-mediated inhibition of
NK cell antitumor toxicity. It is well known that inﬂam-
matory cytokines, such as TNF-α, provoke MSCs to use
iNOS-dependent mechanism for NO production [9, 31].
MSC-derived NO can directly suppress proliferation of
lymphocytes or may increase IDO activity which could result
with the attenuation of NK cell cytotoxicity [9, 31].
5. Conclusions
Our study provides the evidence that systemic application of
MSCs may promote metastasis of lung cancer cells by sup-
pressing antitumor immune response. These ﬁndings raised
serious concerns regarding the safety of intravenous applica-
tion of MSCs in patients who have genetic susceptibility for
malignant diseases.
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